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Abstract 
The global burden of disease associated with wounds is an increasingly 
significant public health concern. Current treatments are often expensive, 
time-consuming and limited in their efficacy in chronic wounds. The challenge 
of overcoming current barriers associated with wound care requires innovative 
management techniques.  
Regenerative medicine is an emerging field of research that focuses on the 
repair, replacement or regeneration of cells, tissues or organs to restore 
impaired function. This article provides an overview of the pathophysiology of 
wound healing and reviews the latest evidence on the application of the 
principal components of regenerative medicine (growth factors, stem cell 
transplantation, biomaterials and tissue engineering) as therapeutic targets.  
Improved knowledge and understanding of the pathophysiology of wound 
healing has pointed at new therapeutic targets. Regenerative medicine has 
the potential to underpin design of specific target therapies in acute and 
chronic wound healing. This personalised approach could eventually reduce 
the burden of disease associated with wound healing. Further evidence is 
required in the form of large animal studies and clinical trials to assess long-
term efficacy and safety of these new treatments.  
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Key messages:  
 Wound healing is a complex process which if disrupted has significant 
implications for patients and health-care services.   
 This article provides an overview of the progress and limitations of how 
growth factors, stem cells, biomaterials and tissue engineering can be 
used to stimulate and accelerate wound healing. 
 Regenerative medicine has the potential to revolutionise wound healing 
by providing therapies that modulate the wound repair cascade, modify 
the wound environment or replace defective tissue. 
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Introduction 
Loss of continuity of the epithelium of the skin results in a wound, which may 
also include damage to the underlying soft tissue structures. Wounds maybe 
caused by a number of insults including mechanical, chemical, biological or 
thermal injuries. Additionally, wounds can be crudely classified as either acute 
or chronic depending on their duration. The burden of disease associated with 
wounds is great with diabetic wounds alone possessing a prevalence of 5-7% 
and cost an estimated €4-6 billion to treat annually in the European Union (1). 
Acute wounds, often as a result of surgery or trauma, can be superficial, 
involving the epidermis and dermis, or full thickness, where the subcutaneous 
layer is damaged. Typically acute wound healing is a well-organized process 
that heals within three weeks. Acute wounds are a common health problem 
with an estimated 11 million people affected and approximately 300,000 
hospital admissions every year in the United States (2, 3).  
Chronic wounds are generally classified as vascular, diabetic or pressure 
ulcers and usually occur as a complication of a disease process. These 
wounds typically persist for a minimum of three months because of an 
interruption in the healing process. This may include a prolonged or excessive 
inflammatory process, persistent infections and inability of dermal and/or 
epidermal cells to respond to regenerative stimuli (4, 5). Chronic wounds are 
a global epidemic with the number of cases dramatically increasing due to an 
ageing population and increased incidence of diabetes and obesity. Hence, 
the disease burden of non-healing chronic wounds continues to increase (6). 
Management of these wounds is expensive as repetitive treatments are 
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required with an estimation of over $20 billion spent each year in the United 
States alone (6). 
Conventional treatment of wounds primarily focuses on identifying and 
removing any precipitating or aggravating factors then allowing the healing 
cascade to proceed. Infection control, wound bed preparation, dressings and 
surgery are the keystones to wound management and maybe used alone or in 
combination to achieve wound healing indirectly (optimisation of the wound to 
allow it to heal by secondary intention) or directly (closure of the wound and 
primary healing). Wound bed preparation allows optimisation of the wound by 
producing a well-vascularized bed with minimal exudate through inflammation 
and infection control, moisture balance and epithelial (edge) advancement. 
Infection control involves the removal of necrotic, devitalized tissue via 
debridement with the use of antimicrobials as required. The use of appropriate 
dressings allows regulation of the wound-healing environment to maintain 
temperature and moisture. Surgical closure of a wound allows direct closure 
of the wound through advancement of the epithelial edges or if this is not 
possible, bridging this closure with skin grafting or a free flap. These wound 
management techniques have been used safely and effectively for many 
years, however, there are limitations such as failure of healing due to 
systemic or local factors, tissue availability and donor-site morbidity where 
tissue transfer is required and antimicrobial resistance. Faced with an ageing 
population and a rise in smoking, obesity and diabetes, the epidemic of 
chronic wounds requires management protocols that can overcome the 
current barriers associated with wound care.  
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Regenerative medicine is an emerging field of research that focuses on the 
repair, replacement or regeneration of cells, tissues or organs to restore 
impaired function. This involves various strategies that include, but are not 
limited to, tissue engineering, stem cell transplantation, biomaterials and 
growth factor therapy. Several reviews have been previously published on the 
topic of regenerative medicine as relevant to wound healing. However, these 
reviews have so far either primarily addressed each of these regenerative 
medicine approaches in isolation (7-9) or focused on chronic wounds (10). In 
this review, we discuss the pathophysiology of wounds and present an 
overview of the latest studies in regenerative medicine and how they maybe 
applied to stimulate and promote healing in the management of both acute 
and chronic wounds.  
 
The Pathophysiology of Wound Healing 
Wound healing is a complex and dynamic process whereby the skin attempts 
to repair itself after injury (Figure 1). The wound repair process can be broadly 
divided into three phases; inflammatory, proliferative and maturation (11). 
During the inflammatory phase, cytokine and chemokine release causes 
neutrophils, macrophages and lymphocytes to migrate to the wound. These 
inflammatory cells then secrete growth factors and provisional matrices which 
promote recruitment of neighbouring epidermal and dermal cells to the wound 
bed (11). The proliferative phase is characterized by the formation of 
granulation tissue, depicted by the increased levels of keratinocyte and 
fibroblast proliferation, epidermal cell migration and extracellular matrix 
synthesis thus resulting in reepithelialisation and angiogenesis (12). The final 
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phase of wound healing entails maturation of the wound and remodelling of 
the extracellular matrix. Differentiation of fibroblasts to myofibroblasts results 
in smooth muscle actin deposition leading to wound contraction and 
replacement of Collagen III by Collagen I in the extracellular matrix. Cells and 
blood vessels that are no longer required are removed via metalloproteinase 
mediated remodelling eventually leading to the formation of an acellular scar 
(13).  
The delicate co-ordinated wound repair process is however susceptible to 
interruption or failure by multiple factors which can be related to the 
characteristics of the wound itself (e.g. contamination or size), specific 
abnormalities in the healing cascade (such as signalling pathway or gene 
expression abnormalities) or the overall physiology of the patient (e.g. 
systemic disease or immune deficiency). These factors may occur in isolation 
or in combination to affect any or all of the phases of the wound healing 
process thus giving rise to impaired healing and a chronic wound. One of the 
best-studied and proposed therapeutic targets is the transition phase between 
inflammation and proliferation of the wound healing process. Whilst the 
inflammatory phase of wound healing is necessary in microbial control and 
clearing of cellular debris, it is critical that this stage is not prolonged and 
there is swift transition to the proliferative stage which allows 
neovascularisation and fibroblast recruitment (14). Prolonged inflammation 
impairs wound healing through leucocyte and matrix metalloprotease 
dysfunction and inflammatory cell over activity (15, 16). Similarly, absence or 
inadequate inflammatory response is responsible for delayed wound healing 
(17, 18). There is increasing evidence of the wide-ranging roles that 
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inflammatory cells play in this complex process and that their function maybe 
dependent on the subset of cells within a population and the stage of the 
healing cascade in which cells are recruited (19-21).  
Another important consideration in wound healing is the role played by the 
fibroblasts and stromal cells recruited during the proliferative phase. The latter 
modulate the immune response through paracrine signalling and promote 
angiogenesis and epidermal cell migration through release of chemokines 
such as Stromal cell-derived factor-1 (22). Fibroblasts directly contribute to 
wound repair by producing extracellular matrix and indirectly through 
chemokine release to perform immune modulation and promote cell migration 
(14).  
Impairment of wound healing due to disruption of the inflammatory or the 
cellular (proliferative response) as described may occur due to a specific 
problem with that part of the healing process such an interleukin deficiency 
(23) or can occur as part of a wider systemic illness such as diabetes mellitus 
(24). Additionally, impaired healing might be due to senescence (25). 
 
Therapeutic Potential of Regenerative Medicine In Wound Healing 
Regenerative medicine encompasses a wide-variety of potential therapies, 
which ultimately aim to promote healing and tissue repair. These therapies 
can be broadly classified as based on growth factors/modulation of signalling 
pathways, stem cells, biomaterials, and tissue engineering, although there is 
usually a great deal of overlap (Figure 2). In this review we describe the 
potential applications of regenerative medicine in wound healing and discuss 
the progress and limitations of the most recent studies relating to this. 
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Growth Factors involved in stimulating wound healing  
Growth factors are biologically active polypeptides that interact with specific 
cell surface receptors in controlling the process of tissue repair. These factors 
primarily promote cell migration into the wound, promote epithelialization, 
initiate angiogenesis and stimulate matrix formation and remodelling of the 
affected area (26). The growth factor families that have been most studied 
and of particular interest in wound healing are epidermal growth factor (EGF), 
transforming growth factor beta (TGFβ), fibroblast growth factor (FGF), and 
platelet derived growth factor (PDGF) (Table 1). There is also emerging 
evidence for the role Stromal cell-derived factor 1 (SDF-1) in regulating 
epidermal cell migration and proliferation during wound repair.   
EGF is secreted by platelets, macrophages and fibroblasts and plays an 
important role in re-epithelialization. In addition to its role in stimulating growth 
of keratinocytes in vitro, Brown et al showed that topical application of EGF 
can accelerate epidermal repair in partial thickness wounds in a clinical study 
(27). This was further supported by a double blind clinical trial by the same 
group, which demonstrated that application of EGF to skin graft donor sites 
accelerated the rate of dermal regeneration (28).  
Platelets, keratinocytes, macrophages, lymphocytes and fibroblasts produce 
TGFβ, which is essential in inflammation, granulation tissue formation, re-
epithelialization, matrix formation and remodelling. Addition of TGFβ to 
incisional wounds in rats were shown to accelerate wound healing through 
increased mononuclear cell infiltration, fibroblast migration and collagen 
deposition by Mustoe et al (29). The mechanism by which this occurs is 
unclear although a study by Pierce et al suggested that TGFβ may be 
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responsible for transient migration of fibroblasts into the wound and direct 
stimulation of collagen production (29).  
PDGF is produced by platelets, keratinocytes, macrophages, endothelial cells 
and fibroblasts and also plays a role in each stage of wound healing (30).  In a 
study of both PDGF and TGFβ, Pierce et al showed that although both growth 
factors accelerated in vivo wound repair, this was through different 
mechanisms of action (31). PDGF was involved in chemoattraction of 
macrophages and fibroblasts thus promoted wound healing through 
stimulating these cells to express growth factors including TGFβ (31). A more 
recent double-blind randomised control trial by Steed et al demonstrated that 
topical application of PDGF to chronic full-thickness diabetic ulcers, to safely 
and effectively stimulate healing (32). 
FGF is produced by keratinocytes, mast cells, fibroblasts, endothelial cells, 
smooth muscle cells and chondrocytes, which was shown to promote 
granulation tissue formation, re-epithelialization, matrix formation and 
remodelling in acute rat wounds (33). This had been previously descried by 
McGee et al who showed that application of recombinant FGF promoted 
faster healing in an acute wound model in rats (34). The effect of FGF on 
wound healing was also investigated in a randomised control trial that showed 
FGF could be used to safely and effectively accelerate healing of chronic 
wounds (35, 36). 
Whilst the role of specific growth factors in wound repair have been 
demonstrated by various studies, a few groups have presented evidence for 
the use of combinations of growth factors to optimise wound healing. Of 
these, platelet-derived wound healing factor (PDWHF) has received attention 
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due to its ease of derivation from autologous sources, evidence of promoting 
healing in chronic wounds without adverse effects and cost efficiency. The 
topical application of PDWHF to promote chronic wound regeneration was 
first shown by Knighton et al who achieved increased closure of chronic 
cutaneous wounds treated with autologous PDWHF (37). This was further 
validated in a blind randomised control trial which also showed that 
autologous PDWHF stimulated reepithelialisation of chronic non healing 
wounds when applied locally (38). The value of using a combination of growth 
factors and the importance of the mode of delivery was reinforced by Yang et 
al who showed that delivery of growth factors (contained in platelet rich 
plasma) accelerated full thickness wound regeneration in mice when using a 
heparin conjugated fibrin carrier (39). 
Recruitment of epidermal stem cells to the wound site from the neighbouring 
uninjured tissue has been shown to induce reepithelialisation (40). Guo et al 
induced full-thickness excisional skin wound model in rats to study the in vitro 
and in vivo role of SDF-1 on epidermal stem cell mediated wound healing 
(22). Skin wounds showed immediate upregulation of SDF-1 peaking at day 7 
after injury with weak expression by day 9 with a similar pattern of expression 
for its cellular receptor (CXCR4). In vitro culture of isolated rat epidermal stem 
cells revealed enhanced migration after addition of SDF-1. Rat wounds 
treated with SDF-1 exhibited accelerated closure compared with controls. 
Additionally this study used an inhibitor of SDF-1 (ADM3100) to demonstrate 
that in vitro cell migration and in vivo wound healing were significantly 
reduced compared with controls and SDF-1 treated groups thus reinforcing 
their findings.   
  12 
Although topical application of growth factors have been shown to accelerate 
wound healing in vitro as well as in a number of animal and human studies 
(Table 1), a number of barriers limit therapeutic application. A major 
consideration is that these factors must be resistant to rapid degradation from 
the wound’s proteolytic environment and have controlled release (26). As 
such, the focus of many studies is now combination of biomaterial research 
with growth factor studies to find a suitable carrier or in combination with stem 
cells to induce differentiation. Since wound repair is a dynamic process, it 
remains to be answered whether delivery of growth factors should be 
sustained or transient and how long they are required. Furthermore, there is 
much interplay between the different cells and components of the wound-
healing cascade. The limitation of many of the studies that have shown the 
usefulness of growth factor application to wounds is that often they study one 
or two of these in isolation. Future studies are required to identify whether this 
is the best approach or if dynamic environment such as that occurs should be 
recreated whereby combinations of growth factors at different time points 
would be more effective. 
 
Stem cells in aiding skin repair 
Stem cells are characterized by their self-renewal capacity, multilineage 
differentiation potential (41) and can be derived from various tissues including 
embryonic, foetal and adult sources. Of these, mesenchymal stem cells 
(MSC) have been most widely studied in wound regeneration research due to 
their safe and relatively easy isolation from tissues like fat and skin. MSC 
derived from skin, fat and bone marrow have shown promising results in 
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induction and acceleration of healing in both acute and chronic wounds. Here, 
we discuss the key outcomes from research into the therapeutic potential of 
epidermal, adipose derived and bone marrow derived stem cells (Table 2). 
Epidermal stem cells (ESC) are an attractive target for developing wound 
therapies because they already resign within the skin, more specifically the 
terminal hair follicle, and are part of the healing response in mammals (40). 
Ma et al isolated these cells from human hair follicles and using in vitro co-
culture assays, showed that they increase proliferation and migration of 
fibroblasts and keratinocytes as well as enhancing angiogenesis by human 
umbilical vascular endothelial cells  (HUVEC) (42). Additionally, application of 
these cells to acute full-thickness wounds significantly reduced the time for 
closure in a type 2 diabetic nude mouse model. In a clinical study, Jimenez et 
al attempted to implanted autologous scalp end terminal hair follicular grafts to 
non-healing leg wounds of ten patients in order to introduce epidermal stem 
cells to these wounds (43). At 18 weeks there was a significant reduction in 
wound size with increased reepithelialisation and vascularisation on histology. 
The conclusion that this healing was mediated by the terminal hair follicles 
was supported in a later randomized controlled trial, which compared 
implantation of grafts containing scalp hair follicles with non-hairy skin grafts 
on chronic wound healing in 12 patients (44). There was a significant 
reduction in the terminal hair follicle treated group.   
Several studies have highlighted the role that adipose derived stem cells and 
adipocytes play in wound healing with immune modulation and paracrine 
signalling shown to be the mode of action. Kim et al investigated the wound 
healing effect of human adipose derived stem cells both in vitro and in vivo on 
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acute wounds (45). Results suggested that ADSCs promoted human dermal 
fibroblast (HDF) proliferation by cell-to-cell direct contact and also by 
paracrine activation through secretory factors. In vitro wound healing models 
also demonstrated ADSC conditioned medium stimulatory effects on 
migration of HDFs. Furthermore, in vivo nude mouse work confirmed wound 
healing effect of ADSCs by reducing wound size and accelerating re-
epithelialization from the edge of the wound after a week. This study provides 
an important insight into the roles played by ADSC in wound healing to reveal 
that they directly promote repair through enhancing the wound healing effect 
of HDF. The work of Schmidt and Horlsey demonstrated that adipocyte 
lineage cells are activated and function during acute skin wound healing in 
mouse models (46). These authors showed that the proliferative phase 
involves the repopulation of adipocytes within skin wounds. An in vivo mouse 
study indicated that immature adipocytes are activated during the proliferative 
phase in parallel with mature adipocytes and fibroblast migration. 
Furthermore, lipoatrophic mice demonstrated impaired wound healing when 
compared with controls suggesting that adipocytes are required for wound 
repair. The findings of this study further support the role of adipocytes and 
their precursors in promoting fibroblast activity in wound healing.  
Bone marrow derived stem cells (BMSC) have also been proposed as a 
potential therapy in wound healing. Their role in acute wound healing was 
explored by Han et al who compared proliferation, collagen synthesis and 
growth factor production of bone marrow stromal cells with those of dermal 
fibroblasts in vitro (47). They found that the amount of collagen synthesis and 
the levels of FGF and the VEGF were much higher in the BMSC group than 
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the fibroblast group suggesting that the BMSC may have superior potential to 
accelerate wound healing than the fibroblasts. In vivo, Uysal et al 
demonstrated that the addition of ADSC or BMSC to acute wounds in rats 
resulted in reduced healing time, increasing angiogenesis and reduced wound 
contraction (48). The mechanisms by which these cells do so maybe related 
to down regulation of α-smooth muscle actin and enhanced FGF expression. 
This is also supported by the work of Wu et al who examined the benefit of 
BMSC in wound healing using an excisional wound splinting model in both 
diabetic and non-diabetic mice (49). They showed that injection of BMSC 
around the wound significantly promoted the healing process in normal and 
diabetic mouse mice possibly through the release of proangiogenic factors 
such as VEGF and angiopoietin.  
The role of BMSC in chronic wound repair was investigated by Kwon et al 
who showed that local or systemic delivery of BMSC to a diabetic wound in 
rats increased wound breaking strength which was associated with increased 
collagen and growth factor expression (50). The BMSC subpopulation that 
originate from the haemopoietic cells pool, increases during the early 
inflammatory phase of wound healing whereas those BMSC from the 
mesenchymal cells pool are predominant within the healed wound. The effect 
of different bone marrow preparations in wound healing was investigated by 
Rodriguez-Menocal et al who demonstrated that whole bone marrow 
enhanced healing in both in vitro wound assays and in mouse models of 
radiation induced delayed wound healing (51). These results suggest that 
different populations of cells in the bone marrow may be responsible for the 
various effects on wound healing observed upon application of BMSCs to the 
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injured skin, such as stimulation of angiogenesis, induction of fibroblast 
migration and reduction of the wound size.  
A small number of clinical studies have supported the therapeutic potential of 
MSC in human wounds. Falanga et al successfully topically delivered 
autologous BMSC to acute surgical wounds and chronic lower extremity 
wounds using fibrin spray (52). They showed accelerated wound healing in 
the acute wounds and significant reduction in size or complete healing in 
chronic wounds by 20 weeks post treatment. The efficacy of autologous 
BMSC in the treatment of chronic non-healing ulcers of the lower extremities 
was compared with standard wound care in a clinical study by Dash et al (53). 
This study demonstrated a significant decrease in ulcer size in the BMSC 
treatment group.  
Whilst the above studies provide evidence of the contribution of MSC to 
wound healing and illustrate that this maybe due to immune modulation, 
paracrine effect on dermal cells and proangiogenic properties, the key 
limitation has been the use of animal models from which it is not always 
possible to directly extrapolate findings to the human wound physiology. 
Additionally, a number of studies use a nude mouse model that may have an 
abnormal response to wound healing due to its immunosuppressed state. 
Furthermore, the short duration of the in vivo experiments again does not 
allow for long-term effect of systemic and local delivery of MSC. Clinical 
studies Whilst the results of clinical studies are promising, they are limited by 
a small sample size, short follow up period and lack of randomised control 
trials. 
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Biomaterials for wound dressing 
Currently, the clinical application of biomaterials in wound healing has been in 
the form of wound dressings which maintain a moist environment and protect 
the wound bed (54). Increasingly biomaterial research has sought to use 
these dressings to actively stimulate wound healing through 
immunemodulation, cell infiltration, generation of extracellular matrix (ECM) 
and vascularization (55). A number of natural and synthetic biomaterials have 
shown promise in acute and chronic wound healing (Table 3). 
Natural polymers such as polysaccharides (e.g. alginates, chitosan), 
proteoglycans and proteins (e.g. collagen, keratin, fibrin) are widely used in 
wound dressings due to their biocompatibility, biodegradation and similarity to 
the ECM. In the acute wound, Rho et al demonstrated increased adhesion 
and spreading of human keratinocytes when cultured on an electrospun 
collagen matrix (56). Natural derived biomaterials such as chitosan have 
shown promise in use as a biological dressing because of inherent properties 
such as haemostatic control, biocompatibility and that they can be modified to 
allow drug delivery. Chitosan alone was shown to promote wound closure of 
pressure ulcers in mouse models in an in vivo study by Park et al (57). 
Additionally, the same in vivo study showed that wound closure was further 
accelerated by using chitosan to deliver FGF and as such was an effective 
drug delivery agent. However, the main limitations of natural polymers are 
their immunogenicity and potential to inhibit cell function in the long term as a 
result of their degradation not being easily controlled (58).  
The use of animal derived acellular matrices allows for the use of a dressing 
with similar properties to the ECM but with low immunogenicity due to 
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decellularisation protocols. This sort of biomaterial has been shown to induce 
closure of chronic diabetic wounds in humans by Yonehiro et al whose cohort 
exhibited increased cell infiltration, vascularisation and integration (59). The 
usefulness of the ECM components of decellularized matrix was again 
demonstrated by Brigido et al who used a synthetic skin substitute matrix as a 
wound dressing which again accelerated wound closure in diabetic patients 
(60).  
Synthetic polymers bypass the immunogenic effects of natural materials and 
are increasingly used to design bioactive dressings. These materials can also 
be easily functionalised to incorporate drugs to create bioactive dressings. 
These capabilities were recently demonstrated by Oh et al who created a 
composite of poly(ε-caprolactone) and chitosan which was then conjugated 
with caffeic acid to generate biodegradable electrospun mats which promoted 
dermal fibroblast cell proliferation and displayed anti-microbial effects in vitro 
(61). Pawar et al loaded electrospun nanofibres with an antimicrobial (Gati), 
which demonstrated controlled-drug delivery, and low cytotoxicity in vitro as 
well as accelerated acute full thickness wound healing in rats (62). 
Biomaterials with broad-spectrum anti-microbial activity were also created by 
Pascual et al who synthesised a polycarbonate hydrogel functionalised with 
methyl iodide (63). These materials exhibited rapid degradation and effective 
killing of gram positive and negative bacteria as well as fungi in vitro. Xie et al 
fabricated a composite chitosan poly(ethylene oxide) nanofibrous scaffold 
embedded with nanoparticles containing vascular endothelial derived growth 
factor (VEGF) and platelet derived growth factor (PDGF) in an attempt to 
mimic the extracellular matrix and promote wound healing (64). These 
  19 
biomaterials exhibited controlled growth factor release, enhanced dermal 
fibroblast proliferation and antimicrobial action in vitro. There was also a 
significant increase in reepithelialisation, angiogenesis, collagen deposition 
and earlier remodelling in acute full thickness wounds dressed with these 
constructs in a rat model. Further demonstration of the versatility of synthetic 
materials was provided by Volkova et al who combined gold nanoparticles 
with cryopreserved fibroblasts in a methylcellulose gel to accelerate wound 
repair in a rat third degree burn model (65). This resulted in accelerated 
wound repair with complete reepithelialisation, organisation of collagen and 
elastic fibres as well as microvessel formation.  
The therapeutic potential for synthetic biomaterial dressings in chronic 
wounds was most recently described by Wang et al who created a composite 
of copper containing bioactive glass and nanofibrillated cellulose aerogel (66). 
This biomaterial supported survival and proliferation of fibroblasts, had a 
proangiogenic effect on HUVEC sprouting assay and was effective in 
inhibiting gram-negative bacteria. They modelled the hypoxic wound 
environment using a 3D spheroid culture system, which showed that this 
biomaterial enhanced HUVEC sprouting and promoted endothelial-fibroblast 
interactions. Chen et al created a self assembling nanofibre gel which was 
conjugated with a human placental DNA sequence (polydeoxyribonucleotide) 
used to treat ischemia and hypoxia (67). This combination promoted 
embryonic fibroblast cell proliferation and increased expression of cytokines 
and proangiogenic growth factors in vitro and induced reepithelialisation and 
granular tissue formation of chronic ulcers in a diabetic mouse model (67).  
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So far studies have shown great potential for biomaterials in enhancing 
wound healing with nanotechnology permitting the modification and 
customisation of material properties to suit the wound repair environment. A 
number of limitations exist, which has made it difficult to identify which 
materials would be best for wide spread clinical translation. As previously 
mentioned, natural materials provide the structural properties required to 
mimic the extracellular matrix but are limited with regards to immunogenic 
potential, expensive fabrication protocols (in the case of non cellular matrices) 
and limited modification potential. Nanomaterials on the other hand are 
extremely versatile with regards to fabrication and design methodology. They 
can be generated as nanofibres or particles depending on whether scaffold, 
dressing or carrier functions are required. An example of this is that whilst 
nanoparticles enable the targeted delivery of active drugs that may not be 
bioavailable in vivo due to poor solubility, short half-life and/or leakage from 
the site of the wound. Further long-term studies are clearly required to also 
assess their safety and bioactivity in the long term. 
 
Skin Tissue Engineering  
Tissue engineering combines many of the key components of regenerative 
medicine such as biomaterial design, stem cell biology and differentiation 
protocol often containing growth factors to replace or repair damaged or 
diseased tissues using biological substitutes. Whilst the previous sections 
have focused on how endogenous wound repair maybe accelerated by the 
application of exogenous substances, this portion of the article will focus on 
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the application of tissue engineering to reconstruct wound defects with 
functional replacement tissue.  
A number of studies have attempted to mimic the extracellular matrix 
environment in order to direct stem cell differentiation and bioengineer skin 
tissue. Decellularized animal matrices preserve native skin architecture and 
have shown promise as suitable scaffolds for skin tissue engineering. 
Nakagawa et al investigated the wound healing effects of human 
mesenchymal stem cells in porcine skin substitute using a nude rat model 
(68). They found that the wound size was considerably smaller using this 
construct and that additionally, this could be used to deliver FGF and further 
accelerate wound healing. In a clinical study, Yoshikawa et al et al cultured 
BMSC on a collagen scaffold to generate an artificial dermis which induced 
skin regeneration in 18 out of 20 patients with intractable dermatopathies (69). 
Nanotechnology can be used to influence cell behaviour and survival. This 
capability was demonstrated by Mashinchian et al who used nanotechnology 
to generate scaffolds with keratinocyte imprints which mediated ADSC 
differentiation into keratinocytes (70). Seeding of human keratinocytes onto a 
hybrid gelatin/nanofiber scaffold by Huan et al provided an engineered 
epidermis which was found to repair skin wounds in a nude mouse model 
(71). This is further supported by another study by Ma et al where the 
combination of BMSC and nanofiber promoted complete and accelerated 
closure of full thickness wounds in a rat model (72). Importantly, the wounds 
demonstrated an intact epithelium with hair follicles and sebaceous glands as 
well as normal collagen deposition.  
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In order to recreate the complexity of normal tissue, it is important to consider 
that skin is comprised of different cell types with distinct functions that work 
together to maintain haemostasis and co-ordinate the response to injury 
(Figure 1). This interdependence was demonstrated through co-culture of 
human ESC with dermal papilla cells (DPC) on a porcine acellular matrix (73). 
ESC/DPC constructs were shown to produce a more structured multi-layered 
stratified epidermis when compared with culture of either of these cells or 
dermal fibroblasts alone. Engraftment of constructs in a full thickness defect in 
nude mice demonstrated improved vascularisation and architecture closer to 
normal skin including the development of hair-bud like structure.    
There is increasing evidence that tissue engineering of skin substitutes may 
eventually provide autologous solutions for wound repair. Protocols that mimic 
the extracellular environment and reproduce the complex cellular 
arrangements have succeeded in bioengineering tissue with similar structure 
to immature skin. It is however still unclear which cell type, scaffold and 
differentiation protocol are optimal. Additionally, most studies have so far 
been limited to regenerating the superficial layers of the skin whereby any 
attempt at skin tissue engineering is likely to require inclusion of the 
subcutaneous tissues, which provide structure and vascularisation.  
 
Conclusion 
Acute and chronic wounds are an increasing public health burden, which is 
only likely to increase due to the rise in diabetic and ageing populations. 
Greater understanding of the pathophysiology of wound healing allows the 
design of more targeted therapies. Regenerative medicine provides a number 
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of opportunities for accelerating and promoting wound healing. Growth 
factors, stem cells and biomaterials can be used to induce repair or indirectly 
to modify the wound environment and stimulate healing. Harnessing the 
power of tissue engineering by combining stem cells and biomaterials also 
has huge potential benefits for improving both function and form for patients.  
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Table 1: Outcomes of growth factor therapy in wound repair. 
Growth Factor  Wound type Study  Summary of outcomes 
EGF 
 
Acute 
 
Clinical 
study 
Accelerates epidermal repair in 
partial thickness wounds (27) 
andepidermal regeneration in 
burns (28). 
TGFβ Acute In vivo Direct application to rat wounds 
increases wound strength, collagen 
deposition and fibroblast influx (29). 
FGF 
 
 
 
Acute 
Chronic 
 
 
In vivo 
Clinical 
study 
 
Accelerates rat wound healing (34) 
Topical application increases 
closure of traumatic ulcers (35) and 
pressure sores (36). 
PDGF 
 
 
 
 
 
 
Acute 
 
 
 
 
Chronic 
 
In vivo 
 
 
 
 
Clinical 
study 
Impaired wound healing associated 
with reduced PDGF expression in 
diabetic mouse wounds (74) whilst 
addition of PDGF accelerated 
wound repair (75). 
Topical PDGF stimulated healing of 
diabetic lower extremity ulcers (32). 
SDF-1 Acute In vitro 
and in 
vivo 
Increases epidermal cell migration 
in vitro and accelerates closure of 
full thickness wounds in rats (22). 
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PDWHF Acute 
 
 
 
Chronic 
In vivo 
 
 
 
Clinical 
study 
Combination of growth factors 
(contained in platelet rich plasma) 
accelerated full thickness wound 
regeneration in mice (39). 
Stimulated reepithelialisation of 
chronic non healing wounds in 
blind randomised control trial (38). 
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Table 2: Mesenchymal stem cell applications in wound healing.  
Cell type Wound type Study  Summary of outcomes 
Epidermal 
stem cells 
Acute In vitro 
 
 
In vivo 
Increases proliferation/migration of 
fibroblasts and keratinocytes and 
angiogenesis (42). 
Accelerates full-thickness wound 
closure in diabetic mice (42). 
Chronic Clinical 
study 
Engraftment of terminal hair 
follicles in chronic leg ulcers 
increased reepithelialisation, 
vascularisation and closure (44).   
Adipose 
derived stem 
cells and  
Adipocytes 
Acute In vitro 
and 
in vivo 
Promote fibroblast migration (46), 
(45), up-regulate collagen I 
production and down regulate 
matrix metalloprotease (45).  
Bone Marrow 
derived Stem 
cells   
Acute 
 
 
 
 
 
 
In vitro 
 
In vivo 
 
 
 
 
 
Clinical 
Increase collagen synthesis and 
growth factor production (47). 
Accelerate healing, increase 
epithelialisation and angiogenesis 
in normal (48) and diabetic wounds 
(49). Optimize wound healing 
properties of porcine skin substitute 
(68) and nanofiber scaffolds (72). 
Accelerate resurfacing of acute 
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study surgical wounds (52) 
Chronic In vivo 
 
 
Clinical 
study 
Improve wound strength, collagen 
I-V and growth factor production in 
diabetic rat wounds (50) 
Reduce lower extremity ulcer size 
(53) and cause closure of non 
healing chronic wounds (69), (76) 
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Table 3: Biomaterials as bioactive dressings for wound repair. 
Biomaterial Wound type Study  Summary of outcomes 
Natural Acute 
 
 
In vitro 
and  
in vivo 
Electrospun collagen nanofibrous 
matrix promotes keratinocyte 
adhesion and spreading (56). 
Chronic In vivo 
 
 
 
 
 
 
Clinical 
study 
Chitosan scaffolds deliver growth 
factors and accelerate pressure 
ulcer healing (57). Gelatin mineral 
composite scaffolds confer 
antibacterial properties and 
promote wound healing in burn 
wounds (77). 
Decellularised matrices promote 
closure of diabetic wounds 
(59),(60) through increasing cell 
infiltration and vascularization (59) 
Synthetic 
 
Acute 
 
 
In vitro 
 
 
 
In vivo 
 
 
Biodegradable electrospun mats 
conjugated with antimicrobial 
promoted fibroblast and displayed 
anti-microbial effects (61).  
Nanofibre mats allow control 
antimicrobial drug release and 
promotes full thickness wound 
healing (62) whilst nanofibrous 
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scaffolds embedded with 
nanoparticle containing growth 
factors induce proliferation in vitro 
and healing in acute full thickness 
wounds in vivo (64).  Gold 
nanoparticles with cryopreserved 
fibroblasts mediated repair in a rat 
third degree burn model (65).   
Chronic In vitro 
 
 
 
 
 
In vivo 
 
Composite copper containing 
bioactive glass and nanofibrillated 
cellulose aerogel stimulate 
angiogenesis and endothelial-
fibroblast interaction in a hypoxic 
wound model (66). 
Self assembling nanofibre gels 
promote reepithelialisation of 
mouse diabetic chronic ulcers (67). 
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Figure 1: An overview of acute wound healing and therapeutic targets 
for stem cells, growth factors and biomaterials. Injury to skin triggers an 
immediate haemostatic response, which results in fibrin clot formation and 
growth factor release. Acute inflammatory cells, platelets and endothelial cells 
are active during the inflammatory and proliferative phases of healing 
whereby they secrete growth factors to promote collagen deposition, 
vascularization and chemotaxis either directly or through paracrine effects on 
other cells such as dermal fibroblasts. In the mature stages of wound healing, 
Dermal fibroblast and myofibroblasts cause wound contraction and scar 
maturation. Stem cells and growth factors have been shown to promote 
wound healing through activity on immune cells, promoting angiogenesis and 
extracellular matrix deposition as well as re-epithelialisation. Biomaterials 
have shown value in accelerating angiogenesis, regulating the wound 
environment as a dressing or used alone or with stem cells to promote re-
epithelialisation. M; macrophage, N; neutrophil, F; Fibroblast, P; platelet, 
RBC; red blood cells, EGF; epidermal growth factor, FGF; fibroblast growth 
factor, PDGF; platelet derived growth factor, VEGF; vascular endothelial 
growth factor, TGFβ; transforming growth factor beta.    
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Figure 2: Therapeutic applications of regenerative medicine in wound 
healing. The key components of regenerative medicine (stem cells, 
biomaterials and growth factors) can be used to target different stages of 
wound healing such as angiogenesis, immunemodulation, cell proliferation 
and extracellular matrix (ECM) deposition in order to induce repair. Tissue 
engineering may combine the use of stem cells, biomaterials and growth 
factors to generate replacement tissue for repairing non-healing chronic 
wounds.  
 
 
  
